Schedule 13D ownership disclosure
Acumen Pharmaceuticals, Inc.
Common Stock, $0.0001 par value per share · CUSIP: 00509G209
Event date: 2026-03-13
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- RA Capital Management, L.P.Reported CIK 0001346824
Shares: 21,101,669.00 · Class: 29.5%
- Peter KolchinskyReported CIK 0001384859
Shares: 21,101,669.00 · Class: 29.5%
- Rajeev ShahReported CIK 0001619841
Shares: 21,101,669.00 · Class: 29.5%
- RA Capital Healthcare Fund, L.P.Reported CIK 0001315082
Shares: 19,103,785.00 · Class: 26.8%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-26-029538
- Form type
- SCHEDULE 13D/A
- Filer
- Acumen Pharmaceuticals, Inc.
- CIK
- CIK 1576885
- Filed
- Mar 17, 2026
- Reporting period
- Mar 13, 2026
- Description
- Schedule 13D beneficial ownership